Insight
Artificial Intelligence-Augmented Integration of Multiomic Information Reveals Actionable Oncologic Signatures
Presented at the AMP Annual Meeting & Expo in November 2026, this poster examines how AI-augmented multiomics can unlock insights into cancer biology. It demonstrates how the integration of genomic, transcriptomic, and proteomic data revealed actionable oncologic signatures, identified a complex dual disease state in multiple myeloma, and highlighted targeted therapeutic opportunities to support more informed treatment decisions.
Complete the form below to access this scientific poster.
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
